Compare OPRX & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | LFCR |
|---|---|---|
| Founded | 2006 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.2M | 308.0M |
| IPO Year | N/A | N/A |
| Metric | OPRX | LFCR |
|---|---|---|
| Price | $12.18 | $8.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | ★ 241.3K | 151.2K |
| Earning Date | 11-06-2025 | 01-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | $109,506,000.00 | ★ $128,867,000.00 |
| Revenue This Year | $19.77 | $2.80 |
| Revenue Next Year | $11.33 | $11.51 |
| P/E Ratio | $6,661.29 | ★ N/A |
| Revenue Growth | ★ 24.18 | 0.47 |
| 52 Week Low | $3.99 | $4.76 |
| 52 Week High | $22.25 | $8.85 |
| Indicator | OPRX | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 59.44 |
| Support Level | $12.23 | $7.32 |
| Resistance Level | $13.00 | $8.43 |
| Average True Range (ATR) | 0.79 | 0.40 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 16.39 | 86.49 |
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.